Rivogenlecleucel

Leukemia

Bellicum PharmaceuticalsCell therapyPhase 1Active

D

29/ 100

Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence: 17/ 100
Competitive Position: 65/ 100

Competitive context

124 Active assets in the Leukemia cohort.

Asset / Sponsor	Phase	Rating
VINCRISTINE SULFATE Inhye Ahn	Phase 3	BB
ASPARAGINASE Gruppo Italiano Malattie EMatologiche dell'Adulto	Phase 3	BB
THIOGUANINE ANHYDROUS Incyte Corporation	Phase 3	BB
Idarubicine Affiliated Hospital of Nantong University	Phase 3	BB
Daunorubicin Richard Stone, MD	Phase 3	BB

View all 50 →

Same molecule, other indications

Rivogenlecleucel is also rated in:

acute myeloid leukemiaDormant

CCC

Indicative ·

48 / 100

myelodysplastic syndromeDormant

CC

Indicative ·

44 / 100

inborn error of immunityDormant

C

Indicative ·

39 / 100

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.